Research library

Key finding

This publication examines [effect of the heptapeptide semax on the human electroencephalogram].

Key finding

Heptapeptide Semax (MEHFPGP) is the fragment of ACTH(4-10) analogue with prolonged neurotropic activity.

Key finding

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analog of the adrenocorticotropin fragment (4-10) which after intranasal application has profound effects on learning and exerts marked neuroprotective activities.

Key finding

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analogue of the N-terminal fragment (4-10) of adrenocorticotropic hormone which, after intranasal application, has profound effects on learning and memory formation in rodents and humans, and also exerts marked neuroprotective effects.

Key finding

The heptapeptide Semax, an analogue of the N-terminal adrenocorticotropic hormone fragment (4-10) (ACTH(4-10)), has been shown to exert a number of neuroprotective effects.

Key finding

The study reports that intranasal administration of Semax for 6 days decreased the volume of cortical infarction and improved retention and performance of conditioned passive avoidance response.

Key finding

Early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance.

Key finding

Psychostimulants, such as methylphenidate, are currently the most common used drug therapy for children with attention-deficit hyperactivity disorder (ADHD).

Key finding

Brain stroke continues to claim the lives of million people every year.

Key finding

This publication examines heptapeptide semax attenuates the effects of chronic unpredictable stress in rats.

Key finding

In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of "Semax" were investigated to define the preparation's stability and mobility in the electric field.

Key finding

Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke.

Key finding

The effects of nootropic drug Semax on the neuronal network of the brain were studied by the resting state functional magnetic-resonance imaging (resting state fMRI).

Key finding

One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined.

Key finding

Current antidepressant therapy shows substantial limitations, and there is an urgent need for the development of new treatment strategies for depression.

Key finding

The Semax (Met-Glu-His-Phe-Pro-Gly-Pro) peptide is a synthetic melanocortin derivative that is used in the treatment of ischemic stroke.

Key finding

Cerebral ischaemia is the most common cause of impaired brain function.

Key finding

Semax affects several biological processes involved in the function of various systems.

Key finding

Consisting of a fragment of ACTH(4-7) and C-terminal PGP tripeptide, the polypeptide Semax is successfully used for acute stroke therapy.

Key finding

Neurotrophins are a family of structurally related proteins that regulate the survival, differentiation, and maintenance of function of different neuron populations.